Global Performance Enhancing Drugs Market Size, Share, Forecast Report, 2020-2027

Performance enhancing drugs are chemical agents designed to provide an advantage in athletic performance. Muscle enlargement, increased blood’s oxygen carrying capacity are some of the effects induced by the consumption of the performance enhancing drugs. In 2015, according to Health Research Funding ~1,084,000 Americans were reported to use anabolic performance enhancing drugs. Along with such trends in the usage of the performance enhancing drugs, increasing acceptance is facilitating the market growth. Approximately 57% of the steroid users said that they would continue to use steroids even if it shortens there life. Moreover, increasing use of the anabolic steroids for the treatment of medical conditions such as anaemia, certain kinds of breast cancer besides others is expected to fuel the market growth during the forecasted period. However, the use of such drugs leads to various side effects. Some of the side effects observed in males are acne, diminished sperm production; in females, masculinization, heart attack, etc. Moreover, in 2014 according to the Health Research Funding, the percentage of positive tests for anabolic drugs doping in world was about 50.6%. Such cases of doping made the governments to formulate strict guidelines for the usage and sales of performance enhancing drugs. This is expected to restrict the market growth during the forecasted period.
The global market for performance enhancing drugs is expected to grow at an approximate CAGR of 4.8%.
Segmentation

The global performance enhancing drugs market is segmented on the basis of types, products, and end users.

On the basis of types, the market is segmented into ergogenic aids, nootropic, and others. The ergogenic aids segment by types is sub-segmented into anabolic steroids, dehydroepiandrosterone (DHEA), human growth hormone, and others. The nootropic segment by types is further segmented into racetams, ampakines, choline & acetylcholine intermediates, others.

On the basis of the products, the market is categorised into pills, injections, patches, and others

On the basis of end users, the market is segmented into athletes, body builders, students, militaries, and others.
Key players for global performance enhancing drugs market

The key players in the global performance enhancing drugs market are Taj Pharmaceuticals Limited. (India), Balkan Pharmaceuticals. (Europe), Bayer AG (Europe), AstraZeneca (Europe), Novo Nordisk A/S (Europe), BrainAlert, LLC (U.S.), Douglas Laboratories. (U.S.), Onnit Labs, LLC. (U.S.), Eli Lilly and Company. (U.S.), and others.